Bitte benutzen Sie diese Kennung, um auf die Ressource zu verweisen: https://doi.org/10.21256/zhaw-2025
Publikationstyp: Beitrag in wissenschaftlicher Zeitschrift
Art der Begutachtung: Peer review (Publikation)
Titel: Development of coverage with evidence development for medical technologies in Switzerland from 1996 to 2012
Autor/-in: Brügger, Urs
Ruckstuhl, Andreas
Horisberger, Bruno
Gratwohl, Alois
DOI: 10.21256/zhaw-2025
10.1017/S0266462314000233
Erschienen in: International Journal of Technology Assessment in Health Care
Band(Heft): 30
Heft: 3
Seite(n): 253
Seiten bis: 259
Erscheinungsdatum: 7-Aug-2014
Verlag / Hrsg. Institution: Cambridge University Press
ISSN: 0266-4623
1471-6348
Sprache: Englisch
Schlagwörter: Health technology assessment; Coverage with evidence development
Fachgebiet (DDC): 610: Medizin und Gesundheit
Zusammenfassung: Objectives: The aim of this study was to assess incidence, time frame, and outcome of “Coverage with Evidence Development” (CED) decisions in the Swiss Basic Health Insurance scheme. Methods: Analysis of all controversial medical technologies submitted to review by the Swiss Federal Office of Public Health (FOPH) from 1996 to 2012 with focus on decisions with constraints. Description of types of technology, type of initial decision, duration of evaluation period, final decision, and search for potential factors associated with changes over time. Results: Forty-five (37.5 percent) of 120 controversial health technologies were classified as “yes, in evaluation, reimbursed” for a certain period of time and thirty-five (29.2 percent) as “no, in evaluation, not reimbursed” by the Federal Department of Home Affairs from 1996 to 2012. The rate of CED decisions ranged between zero and nine per year and was influenced by type of technology and calendar year. Forty-four of forty-five decisions were subject to further restrictions, to a “center or a specialist” (76 percent), “indications” (49 percent), “registry” (31 percent), or “other” (49 percent). The time to a final decision ranged from 1.5 to 11 years (median, 6 years). No factors associated with initial decision and final outcome could be identified. Conclusions: CED as a reality in Switzerland might have enabled patients to obtain access to promising technologies early in their life cycle. CED might have acted as a trigger to a successful implementation of a comprehensive national registry. The lack of qualitative data stresses the urgent need for evaluation of the HTA decisions and their impact on patient outcome and costs.
URI: https://digitalcollection.zhaw.ch/handle/11475/7264
Volltext Version: Publizierte Version
Lizenz (gemäss Verlagsvertrag): CC BY-NC-SA 3.0: Namensnennung - Nicht-kommerziell - Weitergabe unter gleichen Bedingungen 3.0 Unported
Departement: School of Engineering
Organisationseinheit: Institut für Datenanalyse und Prozessdesign (IDP)
Enthalten in den Sammlungen:Publikationen School of Engineering

Dateien zu dieser Ressource:
Datei Beschreibung GrößeFormat 
2014_Ruckstuhl_development_of_coverage_with_evidence.pdf252.1 kBAdobe PDFMiniaturbild
Öffnen/Anzeigen
Zur Langanzeige


Alle Ressourcen in diesem Repository sind urheberrechtlich geschützt, soweit nicht anderweitig angezeigt.